Skip to content
See the World Through ScienceA project of ALLATRA

FDA Approves a Daily Tablet for the Brain Symptoms of Type 3 Gaucher Disease

Science

Republish this story

Our work is licensed under Creative Commons BY-NC 4.0. You may republish this piece for free — with credit to ALLATRA Media and a link to the original, unedited beyond length trims, and not for commercial use.

Read the full license

A modern limestone and glass office building with a brick wing, framed by trees under a clear sky, on the Food and Drug Administration's White Oak campus in Silver Spring, Maryland.
The Food and Drug Administration's White Oak campus in Silver Spring, Maryland, the agency's headquarters, photographed April 30, 2010 (illustrative)."FDA Bldg 31 - Exterior (5161375422)" by The U.S. Food and Drug Administration, via Wikimedia Commons, Public domain

The U.S. Food and Drug Administration approved Infilbray (venglustat) tablets on Nov. 18, 2026 for the neurological symptoms of Type 3 Gaucher disease in adults and children weighing at least 15 kg, about 33 pounds. The agency describes it as the first treatment cleared for those symptoms, which include trouble with balance, coordination, speech, memory and thinking.

It is a rare inherited disorder in which a missing or faulty enzyme leaves the body unable to break down certain fatty substances, so they collect in organs, tissues and the brain. The FDA says the once-daily tablet crosses the blood-brain barrier and blocks the enzyme that assembles those substances, reducing the buildup in the brain as well as the rest of the body.

"For patients with Type 3 Gaucher disease, harmful substances build up in the brain without a way to stop them, but this drug's ability to cross the blood-brain barrier means it can get to the source of the buildup driving the neurological symptoms," said Acting FDA Commissioner Kyle Diamantas.

The agency bases the approval on a randomized, double-blind, multicenter study in 43 patients aged 12 and older, all of whom had been on enzyme replacement therapy and whose disease outside the nervous system had stabilized. For 52 weeks, participants either took Infilbray once a day or stayed on infusions every two weeks — therapy the agency describes as treating the effects of the disease outside the nervous system. At the end, the Infilbray group had improved on a score that combined a measure of ataxia, a loss of muscle control and coordination, with a measure of cognitive function.

According to the release, the most frequent side effects are stomach and bowel symptoms and effects on mood, and serious psychiatric risks, including suicidal ideation and behavior, have been reported. Animal studies pointed to possible clouding of vision in younger patients, and to harm to a developing fetus if the drug is taken during pregnancy.

The FDA granted Infilbray Orphan Drug designation and Priority Review, and the approval went to Genzyme Corporation, a Sanofi company.

Sources

Medical Disclaimer: This content is provided for general informational and educational purposes only. It is not medical advice and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition, concern, symptom, or treatment decision.

Spot an error?

Spot an error?

Report an error

Spotted a mistake on this page? Tell us what's wrong and our editors will take a look.

What kind of problem?

Only if you'd like us to be able to follow up. We won't use it for anything else.

We correct mistakes openly. Select any text to flag it. Fixes are logged under our Corrections Policy.

Report an error

Reporting on

FDA Approves a Daily Tablet for the Brain Symptoms of Type 3 Gaucher Disease

What kind of problem?

Only if you'd like us to be able to follow up. We won't use it for anything else.

We read every report. Corrections are logged publicly.